Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 377 participants.

Also called NCT01652716

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 377 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01652716
Other papers using this trial's data
  • Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes Diabetes, obesity & metabolism, 2018-01 DOI, PubMed 28685973, PMC5724491 In the PMC Open Access subset under CC BY-NC.
  • Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study BMJ open diabetes research & care, 2020-10 DOI, PubMed 33037036, PMC7549491 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01652716. Randomized; no masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2015-09-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes
Acronym
DURATION-NEO-1
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Exenatide once weekly suspension
Intervention (Drug)
Exenatide twice daily
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01652716
Content hash
9d1b52884fc0cb726a6746f1a3bcbd97a2a30aca430acc9d54a26e39f0a0bbc7